Clinical trial NCT02113904: Clinical Trial Using Humira in Netherton Syndrome
Official title: Phase II Clinical Trial Using Humira in Netherton Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Netherton Syndrome
Keywords: Netherton syndrome
Adalimumab
TNF-alpha
Orphan genetic syndrome
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2014-04-15
Enrollment: 11
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of this studies therapeutic : to determine the effect of Adalimumab (HumiraR) on clinical inflammatory manifestations of patients with Netherton syndrome after 3 months of treatment , with a post treatment period follow-up of 3 months.

Second objectives are To evaluate the safety of Adalimumab in the context of NS To evaluate the improvement of the quality of life at 3 months To evaluate the improvement of pruritus and pain in the patients To study markers of inflammatory and allergy in NS prior and after treatment Benefit of the study An improvement by at least 20% of the cutaneous signs in these patients who suffer from a genetic incurable, chronic, painful and very afflicting disease would be of a great help for these patients. NS is a major source of social exclusion.

Risks They are inherent to the risks of biotherapies, especially for an anti-TNF therapy, they comprise a risk of infection. Cutaneous infections occur mainly during infancy, and we have therefore chosen to treat patients over 4 years of age in this study.

A close clinical surveillance will be set up (initially every week during the first month of treatment, then every month). This will represents a large number of visits but will provide a high level of security.

Benefits/risks ratio In the absence of curative treatment for these patients with a severe genetic skin disease, the benefits/risks ration clearly appears to be in favour of an expected benefit.

Detailed description: Netherton syndrome (NS) is a rare (incidence is estimated at 1 in 100 000) but severe genetic skin disease characterized by scaly erythroderma at birth, abnormal hair and severe psoriasiform /atopic dermatitis-like lesions with high IgE levels and allergic manifestations. It has considerable impact on the quality of life of patients, as a result of inflammatory and painful flares, the chronicity of the lesions, severe growth retardation with definitive short stature.

NS is caused by loss of function SPINK5 mutations which lead to unregulated epidermal protease activity : kallikrein 5, kallikrein 7 and elastase proteases are found overactive following loss of inhibition. Secondly, KLK5 activates PAR-2 receptors at the keratinocyte surface leading to the activation of the NF-KB pathway and the release of different pro-inflammatory cytokines such TNF-alpha .

There is no specific treatment for NS. The different therapeutic attempts by Soriatane (acitretin) have worsen the skin inflammation and dryness. The use of topical calcineurin inhibitors (Tacrolimus) has sometimes improved skin inflammation but with an important systemic diffusion. The use of immune suppressive drugs in severe patients with NS followed in our labelized Centre (Cyclosporine, methotrexate, mycophenolate mofetil) have not brought a significant and durable improvement. So NS is a very distressing genodermatosis.

For these clinical and biological considerations, a benefit with anti TNF treatment could be expected and the evaluation of such treatment is justified in NS. The clinical case of an adult patient with severe NS, improved by anti-Tnf treatment has recently been published in the literature

Eligibility criteria: Inclusion Criteria:

* Patient over 4 years of age at the time of enrolment
* Patient with a clinical, immuno-histochemical and/or molecular diagnosis confirmed
* Vaccinations to date
* Informed consent form signed by the patient and/or his parents (or the legal authority) if the patient is a child
* Patient with social security coverage

Exclusion Criteria:

* Ongoing severe infections
* Well known allergy to one of Adalimumab ingredients
* Allergy to xylocaine
* Ongoing treatment to immunosuppressive drugs and biotherapies
* History of malignancy
* Heart, renal, haematological and/or confirmed hepatic involvement
* Pregnant, or breastfeeding, patients
* Anomalies of the standard balance sheet: neutropenia \< 1000/mm3, polynucleose \> 12 000 / mm3 - lymphopenia \< 1000 / mm3 - anemia \< 9g / 100ml - thrombocytopenia \< 150 000 /mm3, thrombocytosis \> 500 000/mm3 - transaminase \> 3N

Primary outcomes:
measure: SN-EASI score and EASI score
timeFrame: month 3
Secondary outcomes:
measure: SN-EASI score and EASI score
timeFrame: at inclusion before treatment
measure: SN-EASI score and EASI score
timeFrame: month 6
measure: Number of participants with adverse events
timeFrame: month 3
measure: CDLQI and DLQI
timeFrame: at inclusion before treatment
measure: CDLQI and DLQI
timeFrame: month 3
measure: CDLQI and DLQI
timeFrame: month 6
measure: Improvement of pain
timeFrame: month 3
measure: Improvement of pruritus
timeFrame: month 3
measure: Hair growth
timeFrame: month 3
measure: Circulating inflammatory response (pro-inflammatory cytokines) cutaneous inflammatory response
timeFrame: month 3
measure: Circulating inflammatory response (pro-inflammatory cytokines) cutaneous inflammatory response
timeFrame: month 6
Other outcomes:
Locations:
city: Paris
country: France
facility: Necker Enfants Malades hospital
Study officials:
affiliation: : Department of Dermatology, Necker Enfants malades hospital, University Paris Descartes 149 rue de sèvres 75015 Paris, France
name: Christine Bodemer, MD, PhD
role: STUDY_CHAIR
References: